News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BerGenBio AS Presents Promising Therapeutic Candidate in AML at American Society of Clinical Oncology



6/3/2013 7:16:56 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BerGenBio AS, an emerging oncology biopharma company, has presented data on the importance of the receptor tyrosine kinase, Axl, in acute myeloid leukemia (AML) at the ASCO Annual Meeting 2013, in Chicago, IL. The research, completed by a team led by Dr Sonja Loges from the University Hospital Hamburg-Eppendorf, suggests that Axl represents a novel prognostic marker and potential therapeutic target in AML.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES